No Data
No Data
Yirui Biology (300942.SZ): The current situation of accounts receivable collection for the company is stable.
Gelonghui September 26th | Yirui Biology (300942.SZ) recently stated during a specific stakeholder research that the company's current accounts receivable repayment situation is stable. Different types and regions of customers have varying repayment cycles for accounts receivable, with government customers being mainly affected by bidding requirements, local fiscal budgets, and other factors. The company also adopts flexible management by prepaying part of the accounts and using various payment modes based on specific customer situations.
Yirui Bioscience (300942.SZ): has successfully opened blank markets in France, Germany, Switzerland, Portugal, Morocco, etc.
Eirui Biology (300942.SZ) stated at the investor relations event on September 14 that in the first half of 2024, the company has successfully opened up blank markets in France, Germany, Swiss franc, Portugal, Morocco, etc., and achieved wide recognition and good feedback for dairy products and other testing products in markets such as Turkey, Brazil, etc. At the same time, the company further develops potential customer groups, enhances customer stickiness and satisfaction by accelerating the expansion of international government projects for pesticide residue rapid testing products, and providing customized solutions for testing requirements in different countries and regions.
Yirui Biotech: Summary of the 2024 Semi-Annual Report
Yirui Biotech: 2024 Semi-Annual Report
Yirui Bio (300942.SZ) released its performance for the first half of the year, with a net loss of 1.5595 million yuan.
Yirui Biotechnology (300942.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
In the first half of the year, Yirui Biological (300942.SZ) reported a net loss of 1.5595 million yuan.
Gelonghui August 29th | Yirui Biological (300942.SZ) released the semi-annual report for the year 2024, with a reported half-year revenue of 0.104 billion yuan, a 7.55% decrease year-on-year; the net income attributable to the shareholders of the listed company was -1.5595 million yuan, narrowing the loss year-on-year; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was -5.2591 million yuan; the basic earnings per share was -0.0039 yuan.
No Data
No Data